Gao Kun, Sun Jin, Liu Kai, Liu Xiaohong, He Zhonggui
Department of Biopharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China.
Drug Dev Ind Pharm. 2008 Nov;34(11):1227-37. doi: 10.1080/03639040802005057.
Docetaxel, a widely used anticancer agent, has sparingly low aqueous solubility, thus Tween 80 and ethanol need to be added into its formulation, probably resulting in the toxic effects. In this study, we aimed to utilize submicron lipid emulsions as a carrier of docetaxel to avoid these potential toxic vehicles. Preformulation study was performed for rational emulsions formulation design, including drug solubility, distribution between oil and water, and degradation kinetics. Supersaturated submicron lipid emulsion of docetaxel was prepared by temperature elevation method. Soya oil and Miglyol 812 can incorporate docetaxel up to 1.0% (drug to lipid ratio) and were used as the oil phase of emulsions. The optimal formulation of docetaxel is composed of 10% oil phase, 1.2% soybean lecithin, 0.3% Pluoronic F68, and 0.4 or 0.8 mg/mL docetaxel, with particle size in the nanometer range, entrapment efficiency more than 90%, and is physicochemically stable at 4 and 25 degrees C for 6 months. Animal studies showed that docetaxel emulsion has significantly higher area under the curve (AUC) and C(max) in rats compared to its micellar solution. The results suggested that the submicron lipid emulsion is a promising intravenous carrier for docetaxel in place of its present commercially available docetaxel micellar solution with potential toxic effects.
多西他赛是一种广泛使用的抗癌药物,其水溶性极低,因此需要在制剂中添加吐温80和乙醇,这可能会导致毒性作用。在本研究中,我们旨在利用亚微米脂质乳剂作为多西他赛的载体,以避免这些潜在的有毒载体。为了进行合理的乳剂配方设计,进行了处方前研究,包括药物溶解度、油水分配以及降解动力学。采用升温法制备了多西他赛过饱和亚微米脂质乳剂。大豆油和Miglyol 812可将多西他赛的载药量提高至1.0%(药物与脂质比),并用作乳剂的油相。多西他赛的最佳配方由10%油相、1.2%大豆卵磷脂、0.3%普朗尼克F68和0.4或0.8 mg/mL多西他赛组成,粒径在纳米范围内,包封率超过90%,在4℃和25℃下6个月内物理化学性质稳定。动物研究表明,与胶束溶液相比,多西他赛乳剂在大鼠体内的曲线下面积(AUC)和C(max)显著更高。结果表明,亚微米脂质乳剂有望作为多西他赛的静脉载体,替代目前具有潜在毒性作用的市售多西他赛胶束溶液。